Home » Stocks » INO

Inovio Pharmaceuticals, Inc. (INO)

Stock Price: $12.26 USD 1.87 (18.00%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $12.44 +0.18 (1.47%) Nov 27, 4:59 PM

Stock Price Chart

Key Info

Market Cap 2.08B
Revenue (ttm) 2.11M
Net Income (ttm) -179.73M
Shares Out 169.41M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $12.26
Previous Close $10.39
Change ($) 1.87
Change (%) 18.00%
Day's Open 10.55
Day's Range 10.49 - 12.40
Day's Volume 21,178,705
52-Week Range 2.28 - 33.79

More Stats

Market Cap 2.08B
Enterprise Value 1.81B
Earnings Date (est) Mar 17, 2021
Ex-Dividend Date n/a
Shares Outstanding 169.41M
Float 165.69M
EPS (basic) -1.35
EPS (diluted) -1.32
FCF / Share -0.85
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 56.76M
Short Ratio 6.84
Short % of Float 34.26%
Beta 1.09
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 984.28
PB Ratio 5.43
Revenue 2.11M
Operating Income -125.16M
Net Income -179.73M
Free Cash Flow -141.17M
Net Cash 262.61M
Net Cash / Share 1.55
Gross Margin -3,886.28%
Operating Margin -5,931.57%
Profit Margin -8,517.70%
FCF Margin -6,690.26%
ROA -26.14%
ROE -100.68%
ROIC -70.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 2
Overweight 0
Hold 5
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$13.71*
(11.83% upside)
Low
8.00
Current: $12.26
High
25.00
Target: 13.71
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue4.1130.4842.2235.3740.5710.4613.474.129.806.14
Revenue Growth-86.51%-27.8%19.37%-12.83%288%-22.35%226.98%-57.95%59.41%-
Gross Profit4.1130.4842.2235.3740.5710.4613.474.129.806.14
Operating Income-111-94.09-83.64-76.24-34.28-39.50-19.54-23.49-21.64-19.22
Net Income-119-96.97-88.21-73.74-29.19-36.12-66.03-19.67-15.25-17.61
Shares Outstanding98.7292.5481.7873.2168.2059.1346.0934.1331.5625.80
Earnings Per Share-1.21-1.05-1.09-1.01-0.44-0.64-1.43-0.58-0.48-0.68
Operating Cash Flow-97.85-73.55-63.21-62.56-12.44-29.82-15.38-22.31-19.76-11.94
Capital Expenditures-0.99-2.09-10.29-3.94-2.78-1.38-0.18-0.24-0.16-0.15
Free Cash Flow-98.84-75.64-73.50-66.49-15.22-31.20-15.56-22.55-19.92-12.09
Cash & Equivalents89.5381.2312710516393.6252.7313.7830.3121.84
Total Debt99.51---------
Net Cash / Debt-9.9781.2312710516393.6252.7313.7830.3121.84
Assets14413118717421413288.2945.1461.1156.07
Liabilities13944.0844.7550.3337.9120.2535.3810.2813.248.97
Book Value3.4486.9414212317611152.4634.3547.3146.50
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Inovio Pharmaceuticals, Inc.
Country United States
Employees 190
CEO J. Joseph Kim

Stock Information

Ticker Symbol INO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: INO
IPO Date February 12, 1998

Description

Inovio Pharmaceuticals, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.